3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
3
Completed
2
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Interventions
Everolimus
10
lanreotide
4
Capecitabine
4
pasireotide
3
lutetium Lu 177 dotatate
3
lenvatinib
3
fosbretabulin
3
Temozolomide
3
Sorafenib
3
Paclitaxel
3
Octreotide
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Filgrastim
3
Erlotinib Hydrochloride
3
Doxorubicin
3
trifluridine tipiracil drug combination
2
surufatinib
2
pembrolizumab
2
pegfilgrastim
2
gallium Ga 68 dotatate
2
durvalumab
2
dactolisib
2
Surveys and Questionnaires
2
Surgical Procedures, Operative
2
Sunitinib
2
Rosiglitazone
2
Radiotherapy
2
Panobinostat
2
Mitotane
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Somatostatin
×
Endocrine
×
Clear all
NCT01755182
2016-05-06
LOTUS
National Cancer Institute, Naples
Phase 3
Terminated
1 enrolled